{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '2221.Adverse events that are ongoing at completion of the EOS visit in HZNP-TEP-301 and/or occur prior to dosing on Day 1 will be considered pre-dose AEs. Adverse events', 'occurring or worsening after the dose on Day 1 through the end of the Treatment Period will be considered treatment-emergent AEs (TEAEs). Adverse events occurring or', 'worsening during the Follow-Up Period will be considered postdose AEs. All SAEs that occur from the signing of informed consent through 30 days after study', 'discontinuation will be recorded.', '23. PK samples will be collected prior to, and at the end of, the infusion on Day 1 and Weeks 3 and 9 of the open-label Treatment Period; additional single samples will', 'be collected at Weeks 1, 4, and 24.', '24.', 'If TED treatment has been received since last contact, the subject will be questioned regarding type of treatment and outcome/response.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 14 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Table 6.1 Table of Non-Sponsor Study Responsibilities', 'Clinical drug supply and distribution', 'Immunogenicity and PK laboratory', '7.1.3.4.5.5.1 Overview and Precautions for AESIs', 'In general, the decision to keep a subject on study treatment with teprotumumab should take into', 'consideration potential risks and benefits to the subject. Prior to all future infusions of', 'teprotumumab, these subjects should be pre-medicated with IV diphenhydramine 1 to', '1.25 mg/kg (maximum: 50 mg), IV ranitidine 50 mg, IV dexamethasone 0.4 mg/kg (maximum:', '20 mg), and/or acetaminophen 500 mg. In addition, all future infusions should be administered', 'over approximately 90 minutes (but not less than 80 minutes). Vital signs should be taken', 'every 15 minutes during the infusion.', '7.2', 'Rationale for this Study', 'Horizon is currently conducting a randomized, multicenter, double-masked, placebo-controlled', 'study evaluating the efficacy and safety of teprotumumab in adult subjects with moderate to', 'severe active TED (HZNP-TEP-301). This study (HZNP-TEP-302) is designed to be an open-', 'label extension of HZNP-TEP-301, in which subjects who received 8 infusions of teprotumumab', 'or placebo in HZNP-TEP-301 and were non-responders at the end of the Treatment Period or', 'relapsed during the Follow-Up Period will be offered the opportunity to receive up to 8 infusions', 'of teprotumumab.', '8.1', 'Primary Objective', 'The primary objective is to evaluate the effect of teprotumumab on the proptosis responder rate', '(i.e., the percentage of subjects with a > 2 mm reduction from Baseline in the study eye without', 'deterioration [> 2 mm increase] of proptosis in the fellow eye) at Week 24 the EOT Visit.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 15 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '8.2', 'Secondary Objectives', 'Secondary objectives will evaluate the effect of teprotumumab on the following:', '1.', 'Percentage of subjects with a Clinical Activity Score (CAS) value of 0 or 1 at Week 24', 'the EOT Visit in the study eye.', '2.', 'Mean change from Baseline to Week 24 the EOT Visit in proptosis measurement in the', 'study eye.', '3.', 'Diplopia responder rate (i.e., the percentage of subjects with baseline diplopia > 0 in', 'study eve who have a reduction of > 1 grade with no corresponding deterioration', '1 grade worsening in the fellow eye) at Week 24.', '4.3.', \"Mean change from Baseline to Week 24 the EOT Visit in the Graves' Ophthalmopathy\", 'Quality of Life (GO-QoL) questionnaire overall score.', '8.3', 'Exploratory Objectives', 'Exploratory objectives will evaluate the effect of teprotumumab on the following:', '1.', 'The overall responder rate (percentage of subjects with > 2-point reduction in CAS AND', '> 2 mm reduction in proptosis from Baseline, provided there is no corresponding', 'deterioration 1> 2-point/mm increase] in CAS or proptosis in the fellow eye) at', 'Week :the EOT Visit.', '2.', 'Clinical Measures of Severity individual response status frequencies and percentage of', 'responders for each component of clinical severity at Week 24the EOT Visit.', '3.', 'Mean change from Baseline to Week 24 the EOT Visit in the CAS.', '4.', 'Overall responder rate at Week 24 the EOT Visit-stratified by the level of response (high', 'responders, responders, low responders, and non-responders; see Section 9.6.3.2.1 for', 'definitions).', '5.', 'Mean change from Baseline to Week 24 the EOT Visit in the GO-QoL questionnaire', 'visual functioning (VF) and appearance (A) subscale scores.', '6.', 'Mean change from Baseline to Week 24 the EOT Visit on the motility component of the', 'Clinical Measures of Severity.', '7.', 'Evaluate pharmacokinetic (PK) parameters of teprotumumab to estimate exposure', 'and understand PK-PD relationships.', '9.1', 'Overall Study Design and Plan', 'All subjects who choose to participate will receive up to 8 infusions of teprotumumab (10 mg/kg', 'for the first infusion followed by 20 mg/kg for the remaining 7 infusions) in an open-label', \"fashion.; with the number of infusions determined by the Investigator' s clinical judgment (but\", 'not to exceed 8 infusions)The Baseline (Day 1) Visit of this extension study will occur within 14', 'days after the final visit of Study HZNP-TEP-301 (Week 24 for proptosis non-responders and up', 'to Week 72 for subjects who relapse). During the open-label Treatment Period, study drug', 'infusions are scheduled for Day 1 (Baseline), and Weeks 3, 6, 9, 12, 15, 18, and 21 (with a final', 'visit at Week 24 of the 24-Week Treatment Period). When the Investigator considers', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 16 of 118']\n\n###\n\n", "completion": "END"}